The Federal Antimonopoly service (FAS) has sent the government proposals to support the production of drugs from the essential drugs list cost of below $ 100. The approach proposed by the Agency will reduce the risk of care essential medicines of the lower price segment of the market, to ensure their accessibility for the population, the Ministry informs.
About unprofitability of production of drugs in the low price segment have already stated a few Russian pharmaceutical manufacturers. In the FAS noted that this issue was long overdue and is systemic. “It is directly connected with the registration price at a low economic base in 2010, followed in 2014 by the change rate of the ruble and a systemic failure to enforce market participants annual indexing for inflation. Now our main task – to minimize the risk of deficiency of these drugs,” said Timofey Nizhegorodtsev, head of Department for control over social sphere and trade FAS of Russia.
According to authorities, it is expedient to amend the Rules of re-registration of maximum selling prices for essential medicines in order to specify the rules for re-registration of prices for drugs in the low price segment. In particular, the proposals of the FAS are the introduction of mandatory registration of prices for generics on the basis of indicative parameters and to enable indexing for some generics.
At the same time the FAS Russia believes that the current currency fluctuations should not affect the cost of essential drugs. This will contribute, in particular, the measures taken by the government of the Russian Federation, which allowed to create a certain cumulative margin of safety.
“If you take into account the reduction in customs duties in 2014, as well as annual indexation over the past two years, the margin of safety for foreign drugs for the current year amounted to 17,30 %. The average Euro / ruble rate in 2020 compared to the average rate of revision of prices of 2018 grew by no more than 1.2% and amounted to 75,01 rubles,” – said Timothy Nizhegorodtsev.